Therapeutic synergy of oral taxane BMS-275183 and cetuximab versus human tumor xenografts

Clinical Cancer Research

Volumn 10, Issue 21, 2004, Pages 7413-7417

  Rose, William C ^a   Wild, Robert ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BMS 275183; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COLON CARCINOMA; DRUG EFFICACY; DRUG POTENTIATION; LUNG CARCINOMA; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CELL LINE, TUMOR; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 8444240000     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1045     Document Type: Article

References (27)

1. Trump DL, Egorin M, Ramanathan R, et al. A novel oral taxane (BMS-275183): a phase I trial with evaluation of pharmacokinetics, pharmacodynamics and bioavailability. Proc Am Soc Clin Oncol 2001;20:109.
2. Trump DL, Egorin MJ, Ramesh R, et al. A new oral taxane (BMS-275183): phase I trial with evaluation of pharmacokinetics, pharmacodynamics and bioavailability. Proc Am Soc Clin Oncol 2002;21:100.
3. Broker LE, De Vos FYF, Gall H, et al. A phase I study of the novel oral taxane BMS-275183 given in a continuous, weekly schedule to patients with advanced solid tumors. Proc Am Soc Clin Oncol 2003;22:132.
4. Broker LE, De Vos FYF, Gall H, et al. A phase I trial of the novel oral taxane BMS-275183 in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2004;23:134.
5. Herbst RS, Bunn PA Jr. Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 2003;9:5813-24.
6. Overholser J, Prewett M, Hooper A, Waksal H, Hicklin D. Epidermal growth factor receptor blockade by antibody IMC C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer (Phila.) 2000;89:74-82.
7. Ciardiello F, Bianco R, Damiano V, et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999;5:909-16.
8. Inoue K, Slaton J, Perrotte P, et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 2000;6:4874-84.
9. Prewett M, Rockwell P, Rose C, Goldstein NI. Anti-tumor and cell cycle responses in KB cells treated with a chimeric anti-EGFR monoclonal antibody in combination with cisplatin. Int J Oncol 1996;9:217-24.
10. Wild R, Kan D, Inigo I, et al. Antitumor activity of cetuximab (Erbitux) in human carcinoma xenografts: potentiation in combination with cisplatin and comparisons with gefitinib (ZD1839) monotherapy. Clin Cancer Res 2003;9:6100s.
11. Cunningham D, Humblet Y, Siena S, et al. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2003;22:252.
12. Saltz L, Rubin M, Hochster H, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001;20:3.
13. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 2004;22:2610-6.
14. Govindan R. Cetuximab in advanced non-small cell lung cancer. Clin Cancer Res 2004;10:4241s-4s.
15. Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000;6:3739-47.
16. y-related cell surface antigens. Cancer Res 1990;50:2183-90.
17. Ziober BL, Willson JK, Hymphrey LE, Childress-Fields K, Brattain MG. Autocrine transforming growth factor-alpha is associated with progression of transformed properties in human colon cancer cells. J Biol Chem 1993;268:691-8.
18. Gehan EA. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 1985;52:203-33.
19. Schabel FM Jr. Synergism and antagonism among antitumor agents. In: Pharmacological basis of cancer chemotherapy. Baltimore: Williams and Wilkins; 1975. p. 595-623.
20. Corbett TH, Griswold DP Jr, Wolpert MK, Venditti JM, Schabel FM Jr. Design and evaluation of combination chemotherapy trials in experimental animal tumor systems. Cancer Treat Rep 1979;63:799-801.
21. Carter SK. Planning combined therapy: the interaction of experimental and clinical studies. Cancer Chemother Rep 1974;4(Pt 2):3-11.
22. Rose WC, Long BH, Fairchild CR, Lee FY. Preclinical pharmacology of BMS-275183, an orally active taxane. Clin Cancer Res 2001;7:2016-21.
23. Emoto T, Yoshikawa K, Fujii M, et al. Clinical study of weekly administration of paclitaxel for advanced and metastatic gastric cancer [in Japanese]. Gan To Kagaku Ryoho 2003;30:809-15.
24. Sakamoto J, Morita S, Yumiba T, et al. A phase II clinical trial to evaluate the effect of paclitaxel in patients with ascites caused by advanced or recurrent gastric carcinoma: a new concept of clinical benefit response for non-measurable type of gastric cancer. Jpn J Clin Oncol 2003;33:238-40.
25. Belani CP, Barstis J, Perry MC, et al. Multicenter, randomized trial for stage IIIB or IV non-small cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 2003;21:2933-9.
26. Athanasiadis A, Tsavdaridis D, Rigatos SK, Athanasiadis I, Pergantas N, Stathopoulos GP. Hormone refractory advanced prostate cancer treated with estramustine and paclitaxel combination. Anticancer Res 2003;23:3085-8.
27. Juan O, Albert A, Villarroya T, et al. Weekly paclitaxel for advanced non-small cell lung cancer patients not suitable for platinum-based therapy. Neoplasma 2003;50:204-9.